Valuation: Seres Therapeutics, Inc.

Market Cap 68.56M 60.23M 55.55M 51.97M 97.31M 6.47B 99.45M 667M 258M 3.19B 257M 252M 11.09B P/E 2026 *
-0.94x
P/E 2027 * -1.08x
Enterprise Value 68.56M 60.23M 55.55M 51.97M 97.31M 6.47B 99.45M 667M 258M 3.19B 257M 252M 11.09B EV / Sales 2026 *
5.33x
EV / Sales 2027 * 192x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day+3.43%
1 week+7.11%
Current month-3.28%
1 month-6.60%
3 months-21.33%
6 months-51.67%
Current year-52.42%
1 week 6.52
Extreme 6.52
7.57
1 month 5.31
Extreme 5.31
7.99
Current year 5.31
Extreme 5.31
16.42
1 year 5.31
Extreme 5.31
29.98
3 years 5.31
Extreme 5.31
105.8
5 years 5.31
Extreme 5.31
501.1
10 years 5.31
Extreme 5.31
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
President 51 02/03/2026
Chief Executive Officer 58 01/08/2025
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap.
05-18Sell

Director

-259 0.0027%
05-18Sell

General Counsel

-79 0.0008%
05-18Sell

Chairperson

-77 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+3.43%+7.11%-22.20%-92.73% 68.56M
+0.33%+1.37%+63.66%+123.67% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-14.67% 23.07B
-1.04%+7.91%+3.91%+413.05% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+188.41% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average +0.45%+5.01%+35.93%+105.10% 22.64B
Weighted average by Cap. +0.26%+5.13%+48.48%+121.47%

Financials

2026 *2027 *
Net sales 12.86M 11.3M 10.42M 9.75M 18.25M 1.21B 18.65M 125M 48.39M 599M 48.28M 47.22M 2.08B 358K 315K 290K 271K 508K 33.79M 519K 3.48M 1.35M 16.68M 1.34M 1.31M 57.92M
Net income -70.97M -62.35M -57.5M -53.79M -101M -6.7B -103M -691M -267M -3.31B -266M -261M -11.48B -99.82M -87.7M -80.88M -75.67M -142M -9.42B -145M -971M -376M -4.65B -375M -367M -16.15B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
26/06/26 $7.080 +3.43% 301,492
25/06/26 $6.845 +0.51% 119,931
24/06/26 $6.810 -3.40% 48,870
23/06/26 $7.050 +6.82% 75,176
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.080USD
Average target price
17.00USD
Spread / Average Target
+140.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock